MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Dermatology, Skincare, Medical Aesthetic & Plastic Surgery Companies
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)*
Organization & Developments: Arcutis Biotherapeutics
Parents
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)*
Children
*Late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology.
2020: Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis
2020: Arcutis Biotherapeutics: Interesting, But Needs Cautious Approach Here
2020: Biotech Analysis Central Preview Series: Arcutis Biotherapeutics
2022: Arcutis Biotherapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Arcutis Biotherapeutics: A Name To Accumulate_seekingalpha.com
2022: Arcutis Biotherapeutics: Keeping A Close Eye On Initial Launch Metrics For Zoryve_seekingalpha.com
2022: Arcutis' psoriasis cream Zoryve clinches win in seborrheic dermatitis trial, proving it's no one trick pony in itch
2023: Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning (NASDAQ:ARQT)
2023: Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology'
2024: Arcutis Biotherapeutics: What Lies Ahead_ seekingalpha.com
2024: Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
2024: Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
2024: Arcutis' ZORYVE Wins Glamour's Best Eczema Treatment Award, Targets 26M Patient Market
2025: Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction
2025: Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction
2025: Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period
2025: Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside
2025: Arcutis Biotherapeutics: Topical Derm Player Continues To Execute
2025: Arcutis outlines growth potential with ZORYVE expansions and market penetration
2025: Arcutis wins FDA nod for Zoryve foam for plaque psoriasis
2025: Arcutis: Out Of The Woods, Ready For Commercialization
2025: Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck
Jumps
Finance & Acquisitions: Arcutis Biotherapeutics
Key People: Arcutis Biotherapeutics